Overexpressed in cancer |
Peak |
P |
FDR |
Normal |
Cancer |
Ratio1 |
Assignment |
p741.6 |
0.0001 |
0.0008 |
8.1 |
12.0 |
1.5 |
SM (34:1) K+ |
p750.5 |
<0.0001 |
0.0002 |
7.8 |
14.6 |
1.9 |
|
p772.7 |
<0.0001 |
0.0002 |
5.5 |
9.1 |
1.6 |
PC (32:0) K+ |
p798.6 |
0.0001 |
0.0005 |
7.5 |
14.5 |
1.9 |
PC (34:1) K+ |
n552.6 |
0.0006 |
0.0019 |
3.1 |
3.5 |
1.1 |
|
n588.2 |
0.0001 |
0.0005 |
8.3 |
12.0 |
1.4 |
|
n599.5 |
0.0001 |
0.0008 |
7.3 |
9.6 |
1.3 |
PI (18:0/0:0) |
n616.6 |
0.0004 |
0.0016 |
2.4 |
3.3 |
1.4 |
|
n687.6 |
0.0007 |
0.0023 |
5.8 |
7.5 |
1.3 |
|
n701.7 |
<0.0001 |
0.0001 |
3.4 |
5.5 |
1.6 |
|
n835.6 |
<0.0001 |
<0.0001 |
3.0 |
7.5 |
2.5 |
PI (16:0/18:1) |
n857.7 |
<0.0001 |
<0.0001 |
1.4 |
2.7 |
2.0 |
|
n861.7 |
<0.0001 |
<0.0001 |
1.8 |
4.4 |
2.4 |
PI-Cer (d18:1/22:0) |
n885.7 |
<0.0001 |
0.0002 |
3.0 |
13.9 |
4.8 |
PI (18:0/20:4) |
Underexpressed in cancer |
Peak |
P |
FDR |
Normal |
Cancer |
Ratio1 |
Assignment |
p518.4 |
0.0003 |
0.0015 |
1.7 |
1.2 |
0.7 |
LPC (18:3) |
p524.4 |
0.0002 |
0.0012 |
2.2 |
3.5 |
0.4 |
LPS (18:1) |
p572.3 |
0.0005 |
0.0017 |
2.2 |
1.1 |
0.5 |
|
p650.5 |
0.0002 |
0.0009 |
3.0 |
2.0 |
0.7 |
|
p672.1 |
0.0004 |
0.0016 |
3.6 |
1.5 |
0.4 |
|
p701.6 |
0.0001 |
0.0008 |
2.6 |
1.3 |
0.5 |
|
p705.5 |
<0.0001 |
0.0002 |
5.8 |
3.6 |
0.6 |
|
p717.5 |
0.0008 |
0.0025 |
4.8 |
2.8 |
0.6 |
|
n555.2 |
0.0003 |
0.0015 |
3.1 |
3.5 |
0.7 |
|
n563.2 |
0.0005 |
0.0017 |
4.8 |
3.2 |
0.7 |
|
n584.5 |
<0.0001 |
0.0003 |
14.5 |
6.3 |
0.4 |
|
n620.2 |
0.0001 |
0.0008 |
11.5 |
6.4 |
0.6 |
|
1Ratio, Ratio of cancer to normal;
2p741.6, m/z 741.6 in the positive ion mode;
3n552.6, m/z 552.6 in the negative ion mode
FDR: False Discovery Rate; SM: Sphingomyelin; PC: Phosphatidylcholine; PI: Phosphatidylinositol; PI:Cer, Phosphatidylinositol:ceramide; LPC: Lysophosphatidylcholine;
LPS: Lysophosphatidylserine |